Read This First
This page is not built on clinical evidence. Cost and access are commercial and legal facts, not scientific findings. They come from the approved product's label, the FDA's compounding rules and the structure of US drug pricing, and they change on timescales of months.
Tesamorelin has a list price, a prescription route, a manufacturer and, for one group of patients, an insurance pathway. That makes it the exception in this corner of the library. It also means the cost question has an answer with structure to it, which the unapproved compounds do not.
This page publishes no prices. Egrifta's list price is set by its manufacturer and changes; what a person pays depends on coverage, the indication, and the channel, and the list price is the number least likely to be the one paid. What follows is what determines the money.
How Tesamorelin Pricing Works
Why There Is No Single Price
Egrifta is a specialty injectable, dispensed through specialty pharmacy, with a manufacturer list price at the top of a stack of discounts, rebates and patient-support arrangements that the buyer never sees. The person with commercial insurance and a covered indication pays a copay set by their plan. The person paying cash pays a figure that depends on which pharmacy and whether the manufacturer's support programme applies. The person buying compounded tesamorelin pays a pharmacy's price for a product that is not Egrifta. The person buying a research vial pays a vendor's price for a product that is not tesamorelin in any verified sense.
Those are four different prices for four different things, and a comparison between them is not a comparison of value.
What Is Actually Being Priced?
The approved dose is 2 mg daily of Egrifta SV or 1.28 mg daily of Egrifta WR, which are equivalent.1 One WR vial covers a week, so a month is four to five vials plus the supplied diluent and needles. That is the unit any honest quote is built on.
The cost is open-ended. In the extension phase of the approval trials, visceral fat reaccumulated when patients were switched to placebo, and the authors concluded the effects "do not last beyond the duration of treatment."2 Tesamorelin is a maintenance drug. A monthly figure is a monthly figure for as long as the effect is wanted.
Insurance
Coverage Depends on the Indication, Not the Molecule
Egrifta is approved for reduction of excess abdominal fat in adults with HIV who have lipodystrophy.1 That is the indication payers cover, and coverage typically requires prior authorisation with documentation of HIV, antiretroviral therapy, and abdominal fat accumulation, often with a waist circumference or imaging threshold. Plans vary; the manufacturer's patient support programme exists to navigate them.
For any other use, there is no covered indication. A person without HIV prescribed tesamorelin for visceral fat, liver fat, cognition or body composition is prescribed it off-label, and off-label use is not a basis for coverage. Prior authorisation will fail on the first criterion, and there is nothing to appeal, because the denial is correct on the plan's own terms.
What About the Liver Data?
The strongest evidence beyond the label is for liver fat in people with HIV.3 It is not an approved indication, and payers do not cover it as one. A person with HIV and fatty liver disease may qualify under the lipodystrophy indication if they also meet its criteria; the liver is not the route in.
Can HSA or FSA Funds Be Used?
For a prescription for the approved product, yes, on the ordinary basis that it is a prescribed medicine. For off-label use, the prescription still exists and the expense is still a prescription drug expense; plan administrators generally do not police indication. For compounded product from a pharmacy with a prescription, generally the same. For research vials, no: there is no prescription and no medical expense, and the account holder carries the consequences.
Off-Label Access
Can a Doctor Prescribe It for Something Else?
Yes. Off-label prescribing of an approved drug is lawful and common. What changes is the money and the evidence. The money becomes cash-pay at whatever the channel charges. The evidence becomes a 2012 cognition trial, a 2019 liver trial in people with HIV, and no controlled trial of tesamorelin for visceral fat in people without HIV, which is the use most often sold.43
The label's cautions do not switch off. The contraindications for active malignancy and pituitary disruption, and the monitoring of IGF-1 and glucose, apply whatever the reason for the prescription.1 A clinic prescribing off-label without that monitoring is not prescribing the approved drug as approved; it is prescribing the molecule.
Why Is Compounded Tesamorelin Cheaper?
Because it is not the same product and is not permitted to be sold as if it were.
Tesamorelin can be compounded because it is a component of an approved drug, but not as "essentially a copy" of the commercial product. The FDA's guidance treats a compounded product with the same active ingredient, a similar strength and the same route as a copy unless a prescriber documents a patient-specific difference, and it states that a lower price is not one.5 The compounded product is cheaper because it skips the manufacturing standard, the stability data and the label. The discount is the difference.
That is not an argument that compounded tesamorelin is dangerous. It is an argument that its price cannot be compared with Egrifta's, because one of the two numbers is attached to a verified product and the other is not, and the law does not recognise the second as a substitute for the first.
What the Money Buys
Where Does the Spread Between Channels Come From?
| Channel | What is supplied | What the price includes | What it does not |
|---|---|---|---|
| Specialty pharmacy, on-label, insured | Egrifta | Verified product, label, monitoring under a prescriber, plan negotiation | Anything off-label |
| Specialty pharmacy, off-label, cash | Egrifta | Verified product and label | Coverage; evidence for the use |
| Compounding pharmacy or telehealth | Compounded tesamorelin | A prescription and a pharmacy label | The approved manufacturing standard; in most cases, legal standing under the copy rule |
| Research vendor | Powder labelled tesamorelin | A vial | Identity, a prescription, a label, any oversight |
ONPEPS publishes no prices; read this as reasoning about cost structure rather than a measured breakdown. Each row is a different product, and each step down the table removes something the row above included. The last row removes everything, including the certainty that the peptide in the vial carries the N-terminal modification that makes tesamorelin tesamorelin.
What Does Monitoring Cost?
The label calls for IGF-1 monitoring during therapy, glucose evaluation before and during, and attention to signs of fluid retention and hypersensitivity.1 Those are blood tests and visits, and for an on-label, insured patient they are part of care. For an off-label cash patient they are a recurring cost that a headline monthly figure rarely includes, and for a research-vial user they do not happen at all, which is the cheapest option and the one the label was written to prevent.
The Spending Decision
What Result Is Being Paid For?
On-label: a 15 percent reduction in visceral fat over six months, maintained while treatment continues, with improved triglycerides and no meaningful change in glucose, in people with HIV-associated lipodystrophy.6 That is well measured, and the label states the drug is weight-neutral, so it is a change in where fat is, not how much.1
Off-label in people without HIV: a reasonable extrapolation with no controlled measurement behind it. The mechanism does not obviously depend on HIV, and the diabetes and cognition trials show the drug behaves similarly in other populations.74 But the effect size in a person without lipodystrophy has never been measured, and the trials in people with HIV excluded people with active cancer and ran a year.
A person paying cash for off-label tesamorelin is buying a verified drug for an unverified purpose. That is a better position than most of this library offers, and it is still a bet.
Is It Cheaper Than the Alternatives?
The comparison usually made is with growth hormone, which is more expensive, and with CJC-1295 and ipamorelin, which are cheaper. Neither comparison holds. Growth hormone is a different drug with a different risk profile and its own indications. CJC-1295 and ipamorelin have no approved product, no efficacy data for any body-composition outcome, and in CJC-1295's case a unanimous advisory vote against compounding.8 Tesamorelin is the only GHRH-pathway compound a person can buy with a label. Whether that is worth its price is a question about the person's goal, not about the peptide market.
What Should Be Asked Before Paying?
Is this Egrifta, compounded tesamorelin, or a research vial? The answer determines everything else.
If compounded, what patient-specific reason is documented for not using the approved product?5
What is the monthly cost at the labelled dose, including diluent, needles and monitoring?
Who will order and read the IGF-1 and glucose tests the label requires?
What is the plan if visceral fat has not changed after six months, which the label says is the point to reconsider?1
Does anyone here earn commission on product sales?
What Would Change This Page
A New Indication, a Generic, or a Price Move
A liver fat indication would open coverage for a larger population and is the most plausible label change, though no filing has been announced. Tesamorelin's original patents date from the 2000s, and a generic or biosimilar would change the cash-pay position; ONPEPS is not aware of one approved. The 2025 acquisition of the manufacturer by a contract manufacturing group may change pricing or supply; it has not yet.9
A Note on Price Comparisons
Figures circulate comparing compounded tesamorelin and research vials favourably with Egrifta. The comparison is between products the law does not treat as interchangeable and the buyer cannot verify as identical. ONPEPS does not make it.
Related ONPEPS Coverage
Tesamorelin library entry: the trials, the label and the off-label market
Tesamorelin sourcing and quality: the approved product, the copy and the vial
Sources
Theratechnologies Inc. EGRIFTA WR (tesamorelin) for injection: prescribing information. Revised March 2025. DailyMed. dailymed.nlm.nih.gov
Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. Paywalled. pubmed.ncbi.nlm.nih.gov/18690162
Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. Open access. pubmed.ncbi.nlm.nih.gov/31611038
Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. Open access. pubmed.ncbi.nlm.nih.gov/22869065
US Food and Drug Administration. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act: Guidance for Industry. January 2018. fda.gov
Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. Open access. pubmed.ncbi.nlm.nih.gov/20554713
Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: a randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538. Open access. pubmed.ncbi.nlm.nih.gov/28617838
US Food and Drug Administration. Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024. Approved 21 February 2025. fda.gov
Theratechnologies Inc. Theratechnologies enters into definitive agreement to be acquired by CB Biotechnology, an affiliate of Future Pak. Press release, 3 July 2025. globenewswire.com
Not Medical or Financial Advice
Tesamorelin is a prescription medicine, and treatment decisions belong with a prescriber who has read its label. Coverage decisions belong with the plan. Nothing on this page is a recommendation to buy or not to buy anything; it is an account of what determines what the money would be spent on.
Sources verified 16 September 2026. Pricing, coverage criteria and manufacturer support programmes change frequently. Re-verify before relying on anything here.